Acute Respiratory Distress Syndrome Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers

DelveInsight's, "Acute Respiratory Distress Syndrome Pipeline Insight 2024" report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Acute Respiratory Distress Syndrome pipeline landscape. It covers the Acute Respiratory Distress Syndrome pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Acute Respiratory Distress Syndrome therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Acute Respiratory Distress Syndrome research. Learn more about our innovative pipeline today! @ Acute Respiratory Distress Syndrome Pipeline Outlook [https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Acute Respiratory Distress Syndrome Pipeline Report

* In October 2024:- Dompe Farmaceutici S.p.A- Phase 2, randomized, double-blinded, placebo controlled, multicenter study. All patients will receive therapy in line with current standard-of-care as it pertains to ARDS management (protocolized ventilator management will be made available to all sites in accordance with currently accepted standard of care). Patients will be randomized (1:1) to either reparixin or placebo. Duration of treatment will be 14 days. In this study the IMP will be either reparixin or matched placebo, which will be provided in the form of tablets to be disintegrated for naso-gastric tube administration or administered orally after extubation and between extubation and day 14 should the patient be able to swallow. In such cases the IMP may be administered either intact or crushed and mixed with a vehicle as per speech swallow evaluation.
* In October 2024:- BioAegis Therapeutics Inc- BTI-203 is a randomized, double-blind, placebo-controlled, multicenter, Phase 2 proof-of-concept (POC) study to evaluate the efficacy and safety of rhu-pGSN plus standard of care (SOC) in subjects with moderate-to-severe ARDS (P/F ratio less than or equal to 150) due to pneumonia or other infections. Potential subjects hospitalized with pneumonia or other infections are to be screened within 24 hours of diagnosis of ARDS.
* In October 2024:- LEAF4Life, Inc.- Acute Respiratory Distress Syndrome (ARDS) is a serious condition where people in hospital care suddenly have trouble breathing because of infection, pneumonia, COVID-19 or other disease. People with ARDS may have to be put in an intensive care unit (ICU) and on a ventilator to help them breathe. This trial is to try to find out if injecting a product called LEAF-4L6715 makes the treatment better or worse than what is normally given. LEAF-4L6715 is a product that contains tiny bubbles to slowly release a substance named transcrocetin which scientific studies show may increase oxygen flow and reduce inflamed cells and protect tissues of the body.
* DelveInsight's Acute Respiratory Distress Syndrome Pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Acute Respiratory Distress Syndrome treatment.
* The leading Acute Respiratory Distress Syndrome Companies such as Staidson (Beijing) Biopharmaceuticals Co., Ltd, Cartesian Therapeutics, GEn1E Lifesciences, Aqualung Therapeutics Corp., Theratome Bio, Meridigen Biotech Co., Ltd., Dompe Farmaceutici S.p.A, Veru Healthcare, Windtree Therapeutics, MiNK Therapeutics, Avalo Therapeutics, Inc., Cynata Therapeutics Limited, Thiogenesis Therapeutics Inc., Arch Biopartners, Ibudilast , and others.
* Promising Acute Respiratory Distress Therapies such as STSA-1002, Rhu-pGSN, Reparixin 600mg, Centhaquine, MRG-001, TTI-0102, Dexamethasone , and others.

Stay informed about the cutting-edge advancements in Acute Respiratory Distress Syndrome treatments. Download for updates and be a part of the revolution in cancer care @ Acute Respiratory Distress Syndrome Clinical Trials Assessment [https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Acute Respiratory Distress Syndrome Emerging Drugs Profile

* GEn 1124: GEn1E Lifesciences

GEn 1124 is an investigative small molecule drug being developed in collaboration with GEn1E Lifesciences and Biomedical Advanced Research and Development Authority (BARDA),part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services to support the development of the company's novel therapy for acute respiratory distress syndrome (ARDS), The drug candidate is mitogen activated protein kinase 14 inhibitors .Currently, the drug is in Phase II stage of its development for the treatment of acute respiratory distress syndrome.

* ALT-100: Aqualung Therapeutics Corp.

ALT-100 is a "First in Man" immune-based monoclonal antibody (mAb) being developed by Aqualung Therapeutics Corp. ALT-100 antibody is a revolutionary, next generation antibody therapy. The humanized antibody has been developed and optimized by Fusion Antibodies' revolutionary CDRx humanization and ADD develop ability platforms. This humanized monoclonal antibody will block systemic inflammation and will improve survival in the ARDS. ALT-100 inhibits eNAMPT binding to TLR4.Currently the drug is in Phase II stage of clinical trial for the treatment of acute distress respiratory syndrome.

* STSA 1002: Staidson (Beijing) Biopharmaceuticals Co., Ltd

STSA 1002 is an investigative recombinant anti-human C5a IgG1 monoclonal antibody which acts by targeting complement C5a inhibitors C5a by specifically binding to anaphylatoxin C5a, C5a loses its ability to bind to receptors and blocks C5a-induced Biological functions, such as neutrophil chemotaxis, degranulation and oxygen respiratory burst, etc., while not affecting C5 cleavage and the formation of membrane attack complex (MAC), retaining the bacteriolytic and bactericidal functions of the complement system, thereby achieving the treatment of viruses, etc. Severe pneumonia, acute lung injury or acute respiratory distress syndrome caused by factors. It is administered through oral and subcutaneous route. Currently, the drug is in Phase I/II stage of its development for the treatment of acute respiratory distress syndrome.

* Descartes 30: Cartesian Therapeutics

Descartes-30 is an off-the-shelf (allogeneic) MSC product engineered with Cartesian's RNA ArmorySM cell therapy platform. Descartes-30 expresses a unique combination of DNases in patients and delivers a targeted treatment directly to the site of disease which eliminates neutrophil extracellular traps which are a key driver of inflammation and clotting in acute respiratory distress syndrome. The drug candidate relies on cell replacements mechanism of action. Currently the drug is in Phase I/II stage of clinical trial for the treatment of acute respiratory distress syndrome.

Learn more about Acute Respiratory Distress Syndrome Drugs opportunities in our groundbreaking metastatic prostate cancer research and development projects @ Acute Respiratory Distress Syndrome Unmet Needs [https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Acute Respiratory Distress Syndrome Companies

Staidson (Beijing) Biopharmaceuticals Co., Ltd, Cartesian Therapeutics, GEn1E Lifesciences, Aqualung Therapeutics Corp., Theratome Bio, Meridigen Biotech Co., Ltd., Dompe Farmaceutici S.p.A, Veru Healthcare, Windtree Therapeutics, MiNK Therapeutics, Avalo Therapeutics, Inc., Cynata Therapeutics Limited, Thiogenesis Therapeutics Inc., Arch Biopartners, Ibudilast, and others.

Acute Respiratory Distress Syndrome Pipeline Report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

* Oral
* Parenteral
* Intravitreal
* Subretinal
* Topical

Acute Respiratory Distress Syndrome Products have been categorized under various Molecule types such as

* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy

Discover the latest advancements in Acute Respiratory Distress Syndrome treatment by visiting our website. Stay informed about how we're transforming the future of oncology @ Acute Respiratory Distress Syndrome Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Acute Respiratory Distress Syndrome Pipeline Report

* Coverage- Global
* Acute Respiratory Distress Syndrome Companies- Staidson (Beijing) Biopharmaceuticals Co., Ltd, Cartesian Therapeutics, GEn1E Lifesciences, Aqualung Therapeutics Corp., Theratome Bio, Meridigen Biotech Co., Ltd., Dompe Farmaceutici S.p.A, Veru Healthcare, Windtree Therapeutics, MiNK Therapeutics, Avalo Therapeutics, Inc., Cynata Therapeutics Limited, Thiogenesis Therapeutics Inc., Arch Biopartners, Ibudilast, and others.
* Acute Respiratory Distress Therapies- STSA-1002, Rhu-pGSN, Reparixin 600mg, Centhaquine, MRG-001, TTI-0102, Dexamethasone, and others.
* Acute Respiratory Distress Syndrome Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Acute Respiratory Distress Syndrome Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Acute Respiratory Distress Syndrome pipeline on our website @ Acute Respiratory Distress Syndrome Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Executive Summary
* Acute Respiratory Distress Syndrome: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Acute Respiratory Distress Syndrome- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Drug name: Company name
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* GEn 1124: GEn1E Lifesciences
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I/II)
* STSA 1002: Staidson (Beijing) Biopharmaceuticals Co., Ltd
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* Acute Respiratory Distress Syndrome Key Companies
* Acute Respiratory Distress Syndrome Key Products
* Acute Respiratory Distress Syndrome- Unmet Needs
* Acute Respiratory Distress Syndrome- Market Drivers and Barriers
* Acute Respiratory Distress Syndrome- Future Perspectives and Conclusion
* Acute Respiratory Distress Syndrome Analyst Views
* Acute Respiratory Distress Syndrome Key Companies

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=acute-respiratory-distress-syndrome-pipeline-therapeutics-assessment-companies-products-unmet-needs-market-drivers-and-barriers]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.